Tofacitinib successful treatment of idiopathic twenty-nail dystrophy: a case report

PURPOSE: Twenty-nail dystrophy (TND) is a chronic nail disorder affecting all or some nails and posing a significant therapeutic challenge for dermatologists. Janus kinase (JAK) inhibitors have recently emerged as a promising treatment modality for refractory nail diseases. RESULTS: We report a case of a patient with idiopathic TND for 12 years duration, and successfully treated with oral tofacitinib, which offered a potential new therapeutic choice for this challenging entity. Some successful cases of treating inflammatory nail diseases with Janus kinase (JAK) inhibitors were reviewed. CONCLUSION: Janus kinase (JAK) inhibitors may be a promising therapeutic option for patients with twenty-nail dystrophy.